Recent Updates
Recently added Catalysts
WVE Positive Sentiment Score: 75/100

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

Key Takeaway: Wave Life Sciences Ltd. is set to participate in the upcoming SVB Securities Global Biopharma Conference, where CEO Paul Bolno will host a fireside chat. This event, scheduled for February 16, 2023, highlights the company’s dedication to genetic medicines as it strives to provide treatments for severe diseases. Attendees can access the presentation via a live webcast and find archived replays on the company's investor relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Wave Life Sciences is actively engaging in public forums to discuss its initiatives.
  • The company's commitment to developing life-changing treatments is emphasized.
  • The use of their proprietary PRISM platform indicates innovative approaches in drug development.

Full Press Release Details

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.
A live webcast of this presentation can be found here and will also be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. Replays of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Frequently Asked Questions

When is Paul Bolno participating in the fireside chat?

Paul Bolno will participate in the fireside chat on February 16, 2023, at 10:00 a.m. ET.

Where can I watch the webcast of the presentation?

The live webcast can be found on Wave Life Sciences' corporate website and Investor Relations page.

What does Wave Life Sciences specialize in?

Wave Life Sciences specializes in developing life-changing genetic medicines for serious diseases.

What is the PRISM platform?

PRISM is Wave's proprietary platform for designing and developing stereopure oligonucleotides.

How can I contact Wave Life Sciences for investor relations?

You can contact Wave Life Sciences' investor relations via email at InvestorRelations@wavelifesci.com.

Last updated: Feb 9, 2023